Aberdeen Group
JBIO

Aberdeen Group’s Jade Biosciences JBIO Stock Holding History

Aberdeen Group’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8M Sell
621,108
-246,176
-28% -$5.13M 0.02% 536
2026
Q1 		$12.2M Hold
867,284
– – 0.02% 552
2025
Q4 		$13.4M Buy
+867,284
New +$10.2M 0.02% 551

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group's JBIO Position: Q2 2026 in Review

Aberdeen Group reduced its Jade Biosciences (JBIO) stake by 28% in Q2 2026, selling an estimated $5.13M and leaving 621,108 shares worth $13.8M. The position accounts for 0.02% of the portfolio, ranked #536.

Aberdeen Group first reported a position in JBIO in Q4 2025 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Aberdeen Group held 621,108 shares of Jade Biosciences worth $13.8M as of Q2 2026.
  • Aberdeen Group sold 246,176 Jade Biosciences shares in Q2 2026, an estimated $5.13M.
  • Jade Biosciences made up 0.02% of Aberdeen Group's portfolio in Q2 2026, its #536 holding.
  • Aberdeen Group first reported a position in Jade Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.